Latest news

• GSK's triple COPD therapy tops Symbicort in phase III trial

  These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer

• GSK brings forward triple COPD therapy filing in US

  The company suffered declining respiratory sales through 2015 - although its performance improved in the first quarter of this year thanks to gathering momentum for two-drug combinations Relvar/Breo (vilanterol/fluticasone

• Respiratory return helps GSK to solid first quarter

  Relvar/Breo (vilanterol/fluticasone furoate), Anoro (vilanterol/umeclidinium bromide) and severe asthma debutante Nucala (mepolizumab).

• GSK's Breo fails to show survival benefit in COPD

  GlaxoSmithKline's struggling respiratory division has had more bad news, with new product Breo/Relvar failing to improve survival in a trial involving patients with chronic obstructive pulmonary disease (COPD).

• Boehringer's Spiriva combo approved in first EU markets

  Relvar (fluticasone furoate/vilanterol) which became the first once-daily product of its type, have injected more competition into the marketplace.